| Project/Area Number |
20591764
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
MURATA Hiroaki Kyoto Prefectural University of Medicine, 医学研究科, 客員講師 (90360031)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KIMURA SHINYA 佐賀大学, 医学部, 教授 (80359794)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 悪性骨腫瘍 / 悪性軟部腫瘍 / ビスホスフォネート / 癌 / 悪性軟部腫 |
|---|
| Research Abstract |
The lower dose of third generation bisphosphonates (BPs) significantly prevented lung metastasis for the in vivo effects of BPs, although the higher dose of BPs was required to inhibit the growth of osteosarcoma cells at the primary site. In addition, BPs inhibited the production of vascular endothelial growth factor and reduced the migration, adhesion, and invasiveness of osteosarcoma cells in vitro. Combinationtherapy using BPs and radiation augmented the antitumor effects. From the results ofantitumor effects of BPs against fibrosarcoma cells, BPs arrested the cell cycle in the S phases, inhibited cell proliferation, and induced the apoptosis of their cells. Moreover, BPs augmented the effect of antitumor agents when administered concurrently with them in human fibrosarcoma cells.
|
